On April 5, 2022, Dr. Matthew Spear informed Poseida Therapeutics, Inc. of his intent to resign from his position as the Company's Chief Medical Officer in order to pursue another opportunity. His resignation will be effective as of April 22, 2022 and is not associated with, or attributable to, any disagreement with the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.77 USD | -5.14% | -4.48% | -17.56% |
14/05 | Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises | MT |
14/05 | Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.56% | 283M | |
+19.33% | 125B | |
+13.95% | 109B | |
-3.53% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.62% | 16.64B | |
+0.99% | 13.45B | |
+21.79% | 11.32B |
- Stock Market
- Equities
- PSTX Stock
- News Poseida Therapeutics, Inc.
- Matthew Spear Informs Poseida Therapeutics, Inc. of His Intent to Resign from Chief Medical Officer Position, Effective April 22, 2022